DARE — Dare Bioscience Income Statement
0.000.00%
Last trade - 00:00
- $28.29m
- $11.87m
- $2.81m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 10 | 2.81 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 14.3 | 27.4 | 38.7 | 41.4 | 33.7 |
Operating Profit | -14.3 | -27.4 | -38.7 | -31.4 | -30.9 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -14.3 | -27.4 | -38.7 | -30.9 | -30.2 |
Net Income After Taxes | -14.3 | -27.4 | -38.7 | -30.9 | -30.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -14.3 | -27.4 | -38.7 | -30.9 | -30.2 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -15.1 | -27.4 | -38.7 | -30.9 | -30.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -11.6 | -10.9 | -7.67 | -4.39 | -4.15 |